Clinuvel Pharmaceuticals Ltd (CUV) — Capital Reinvestment Ratio

Latest as of December 2025: 0.01x

Clinuvel Pharmaceuticals Ltd (CUV) has a Capital Reinvestment Ratio of 0.01x as of December 2025, meaning it reinvests 0% of its operating cash flow (AU$12.52 Million) in capital expenditures (AU$149.47K). See Clinuvel Pharmaceuticals Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.01x
Capex / Operating Cash Flow

Operating Cash Flow

AU$12.52 Million
AUD

Capital Expenditures

AU$149.47K
AUD

Data as of

Dec 2025
Most recent filing

Clinuvel Pharmaceuticals Ltd Capital Reinvestment Ratio (2017–2025)

This chart tracks Clinuvel Pharmaceuticals Ltd's Capital Reinvestment Ratio across 9 annual periods.

Annual Capital Reinvestment Ratio for Clinuvel Pharmaceuticals Ltd (2017–2025)

Year-by-year Capital Reinvestment Ratio for Clinuvel Pharmaceuticals Ltd from 2017 to 2025. For live market cap and broader valuation context, see market cap of Clinuvel Pharmaceuticals Ltd.

Year Reinvestment Ratio Operating CF (AUD) Capital Expenditures YoY Change
2025 0.01x AU$41.10 Million AU$298.57K ▼ -95.2%
2024 0.15x AU$37.05 Million AU$5.58 Million ▲ +440.6%
2023 0.03x AU$36.91 Million AU$1.03 Million ▲ +155.5%
2022 0.01x AU$39.87 Million AU$434.44K ▼ -75.4%
2021 0.04x AU$19.26 Million AU$854.33K ▼ -29.2%
2020 0.06x AU$14.19 Million AU$888.83K ▲ +348.8%
2019 0.01x AU$18.46 Million AU$257.62K ▲ +117.3%
2018 0.01x AU$11.69 Million AU$75.12K ▼ -5.6%
2017 0.01x AU$9.92 Million AU$67.48K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow